1) Duchenne muscular dystrophy and 2) Topic of the month: Stroke and stroke care. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Diana Escolar about her paper on weekend versus daily prednisone in Duchenne muscular dystrophy. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Guillain-Barre-like syndrome with thallium poisoning. In the next part of the podcast Dr. Brett Kissela interviews Drs. Ralph Sacco and Larry Goldstein about prevention of stroke part 1. Next week you will hear part 2 and over the subsequent three weeks, Dr. Kissela will interview Drs. Bo Norrving, about other aspects of stroke and stroke care. The participants had nothing to disclose except Drs. Escolar, Fugate, Kissela, Sacco and Goldstein.Dr. Escolar serves on a scientific advisory board for the NIH/NINDS; serves on the speakers' bureau for and has received funding for travel and speaker honoraria from Athena Diagnostics, Inc.; has received speaker honoraria from Kennedy Krieger Institute and Acceleron Pharma; serves as a consultant for Gerson Lheman Group (GLC), Acceleron Pharma, and Medacorp; and receives research support from the NIH, the Muscular Dystrophy Association, and the Foundation to Erradicate Duchenne (FED).Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela has served on the scientific advisory board for for Allergan, Inc.; receives honoraria from Allergan, Inc; receives research support from the NIH; and gave expert testimony in medico legal cases related to stroke. Dr. Sacco serves on a data safety monitoring board indirectly sponsored by Pfizer Inc; serves on the editorial boards of Stroke and Neuroepidemiology; and receives research support from the NIH and the Evelyn McKnight Brain Institute. Dr. Goldstein is a consultant for Allergan, Inc. and Merck Serono; serves on the Steering Committee, SPARCL trial, is a consultant and speaker at meetings in which the SPARCL trial is discussed, Pfizer Inc serves on the Neurology Executive Committee, RESPECT Trial (AGA Medical) Clinical Oversight Committee, and ACT-1 trial (Abbott); and received research support from the RESPECT Trial Site (AGA Medical).